EU H2020 Project "LEONID (Lung cancEr fusiOn geNes: a new dIagnostic Device)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/197568/index.html

LEONID project word cloud

Explore the words cloud of the LEONID project. It provides you a very rough idea of what is the project "LEONID" about.

cheapest hospitals boost detects ihc laboratories customers ivd verification power perform kit medium running data detection least extended device fusions avoiding fish diagnostic hands rearrangements inhibitors kinase solution ready eml4 secondary clinical treatment 450 alk bimind specificity standardization fastest throughput expertise genes entrance passed personal biomarkers scope company ehr speed validation complementary laboratory lung distributors time vitro panel leonid patients tests multiplex standards ce variants pharmacogenetics predictive robustness rate guarantee diatech ros1 labs standardized business sensitivity oncology easiest pgx experimental combination extend assay error reproducibility 85 specialized feasibility interpretation supporting unknown nanostring of first ret samples molecular software geneticlab saving performance losing proprietary reduce fusion cancer tyrosin pathology

Project "LEONID" data sheet

The following table provides information about the project.

Coordinator	DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA Organization address address: VIA SILONE 1 BIS city: JESI postcode: 60035 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://leoniddiatech.blogspot.it
Total cost	1˙704˙000 €
EC max contribution	1˙704˙000 € (100%)
Programme	1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2016-12-31

#	participants	country	role	EC contrib. [€]
1	DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA	IT (JESI)	coordinator	1˙465˙438.00
2	BIMIND SAS DI MARINELLI MARCO VICO MAURIZIO EC	IT (JESI)	participant	155˙000.00
3	GENETICLAB S.R.L.	IT (Pordenone)	participant	83˙561.00

DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA

IT (JESI)

coordinator

1˙465˙438.00

BIMIND SAS DI MARINELLI MARCO VICO MAURIZIO EC

IT (JESI)

participant

155˙000.00

GENETICLAB S.R.L.

IT (Pordenone)

participant

83˙561.00

Project objective

The main scope of LEONID project is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment. The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK. The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility. The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers. For Diatech Pharmacogenetics, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company’s approach of potential European distributors. GeneticLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests’ results and can provide its new software through Diatech PGx or directly.

Deliverables

List of deliverables.
Final event	Documents, reports	2019-05-30 12:53:27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEONID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEONID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

SIME-LMT (2015)

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth